Lisata Therapeutics (NASDAQ:LSTA) Stock Price Down 3.9% – Here’s Why

Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares dropped 3.9% during mid-day trading on Friday . The stock traded as low as $1.92 and last traded at $1.97. Approximately 29,264 shares traded hands during trading, an increase of 35% from the average daily volume of 21,665 shares. The stock had previously closed at $2.05.

Analysts Set New Price Targets

LSTA has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lisata Therapeutics in a research note on Wednesday, October 8th. Zacks Research lowered shares of Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.50.

Lisata Therapeutics Price Performance

The company has a 50-day simple moving average of $2.17 and a two-hundred day simple moving average of $2.39. The stock has a market capitalization of $17.38 million, a price-to-earnings ratio of -0.92 and a beta of 1.09.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.05. Research analysts anticipate that Lisata Therapeutics, Inc. will post -2.66 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Cerity Partners LLC bought a new stake in shares of Lisata Therapeutics during the second quarter valued at approximately $32,000. CIBC Bancorp USA Inc. bought a new position in Lisata Therapeutics in the 3rd quarter worth approximately $37,000. Finally, Ground Swell Capital LLC acquired a new stake in Lisata Therapeutics in the 3rd quarter valued at approximately $62,000. Institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.